Advertisement

Search Results

Advertisement



Your search for ASCO matches 14427 pages

Showing 151 - 200


gynecologic cancers

ASCO20: Final Overall Survival Analysis From SOLO2 in Ovarian Cancer

For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...

gynecologic cancers

Expert Point of View: Robert L. Coleman, MD

Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...

gynecologic cancers

ASCO20: Secondary Surgery May Extend Survival in Recurrent Ovarian Cancer

Two phase III trials provided support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...

gynecologic cancers

ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer

In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...

Expert Point of View: Ana Oaknin, MD, PhD

Ana Oaknin, MD, PhD, Head of the Gynecologic Cancer Program at Vall d’Hebron Institute of Oncology, Barcelona, discussed the PRIMA/ENGOT-OV26/GOG-3012 trial along with the results of the phase III PAOLA-1/ENGOT-ov25 trial of olaparib plus bevacizumab maintenance. All three trials—PRIMA, PAOLA-1,...

gynecologic cancers

ESMO 2019: PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets

In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a...

gynecologic cancers

Novel Drug Approvals and New Indications for Gynecologic Cancers

A number of new drugs and novel indications were added to the treatment armamentarium for gynecologic cancers over the past year. The U.S. Food and Drug Administration (FDA) approvals are noted here. Olaparib, PARP Inhibitor On May 8, 2020, the FDA expanded the indication of olaparib (Lynparza) to...

Expert Point of View: Thomas J. Herzog, MD

Thomas J. Herzog, MD, Deputy Director, University of Cincinnati Cancer Center, who presented a distillation of the PRIMA trial data along with updated results of the phase III PAOLA-1 trial of olaparib plus bevacizumab maintenance, called the data “practice-changing.” “We’ve suspected for a while...

gynecologic cancers

SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer

Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer...

gynecologic cancers

Addition of Olaparib to Bevacizumab Maintenance in Advanced Ovarian Cancer: PAOLA-1 Trial

As reported inThe New England Journal of Medicine by Isabelle Ray-Coquard, MD, PhD, of the Céntre Léon Berard, University Claude Bernard Lyon 1 and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, and colleagues, the phase III PAOLA-1 trial has shown a...

gynecologic cancers

Gynecologic Oncology Highlights 2019–2020 Almanac

Ovarian cancer is associated with the highest risk of mortality among the five most common gynecologic cancers (cervical, ovarian, uterine [endometrial], vaginal, and vulvar) in the United States; in 2020 in the United States, ovarian cancer will be diagnosed in an estimated 21,750 women, and...

gynecologic cancers

Risk‐Reducing Early Salpingectomy and Delayed Oophorectomy Among Premenopausal Women

A study published by Gaba et al in BJOG: An International Journal of Obstetrics and Gynaecology has found that risk‐reducing early salpingectomy and delayed oophorectomy is highly acceptable among premenopausal women at increased risk for developing ovarian cancer—particularly among patients...

sarcoma

Comparing Pazopanib to Doxorubicin in Patients Aged 60 and Older With Soft-Tissue Sarcoma

Doxorubicin is a standard of care in patients with advanced inoperable soft-tissue sarcoma. In the EPAZ study, German researchers tested whether pazopanib showed comparable efficacy to doxorubicin in the first-line treatment of elderly patients with soft-tissue sarcoma. Grünwald et al reported in...

leukemia

FDA Approves Oral Azacitidine as Maintenance Therapy for Adults With AML in First Remission

On September 1, the U.S. Food and Drug Administration (FDA) approved oral azacitidine (Onureg; also known as CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery...

lung cancer
immunotherapy

Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?

After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...

survivorship

Impact of Prior Insurance Coverage Disruptions on Health-Care Access and Affordability for Currently Insured Cancer Survivors

A new study from the American Cancer Society has found health insurance coverage disruptions in the prior year led to issues with health-care access and affordability for currently insured cancer survivors. The study was published by Zhao et al in Cancer Epidemiology, Biomarkers & Prevention....

hematologic malignancies
covid-19

Are Patients With Hematologic Cancers More Vulnerable to the Effects of COVID-19?

A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that, compared with patients who have other malignancies, patients with blood cancers are more vulnerable to the effects of COVID-19 infection. These results were published by Lee et al in The Lancet Oncology. As...

prostate cancer

Metastatic Prostate Cancer: Sorting Through the Treatment Maze

The message still needs to get out that metastatic castration-sensitive prostate cancer should be treated with both androgen-deprivation therapy (ADT) and either docetaxel or an androgen receptor pathway inhibitor. In spite of “overwhelming” support for ADT plus abiraterone/prednisone,...

genomics/genetics

FDA Approves FoundationOne Liquid CDx, a Pan-Tumor Liquid Biopsy Test

On August 28, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test for patients with solid tumors. FoundationOne Liquid CDx is a comprehensive genomic-profiling test that analyzes more than 300 cancer-related genes and multiple...

lung cancer
immunotherapy

ORIENT-11 Trial Shows Sintilimab Plus Chemotherapy Improves Progression-Free Survival in Advanced NSCLC

The first-line setting for patients with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) now has become more complicated, according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual...

cost of care

Web-Based Tool May Help Patients With Cancer Choose the Best Insurance for Their Needs

Given the rising costs of cancer care, many patients with cancer and cancer survivors are challenged by financial toxicity, the burden of care costs. Many struggle to choose a health insurance plan that best meets their needs. Moreover, these challenges are often exacerbated by limited health...

integrative oncology

Acupuncture vs Sham Procedure and Usual Care for Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a debilitating and enduring adverse effect of many antineoplastic agents, which negatively impacts the quality of life of patients with cancer and survivors. Current pharmacotherapy has limited efficacy and causes undesirable effects. In this...

lung cancer
covid-19

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry

Marina C. Garassino, MD, of the Istituto Nazionale dei Tumori di Milano, discusses the global registry she and her colleagues created to track and address the 35% higher mortality risk from COVID-19 among patients with lung cancer who are treated with chemotherapy.

Highlights From the IASLC Virtual Presidential Symposium

This week on The ASCO Post Podcast, we'll first hear about a study of the monoclonal antibody sintilimab in combination with pemetrexed and platinum to treat advanced nonsquamous non–small cell lung cancer. Then we'll review the results of the CheckMate 743 trial, which suggest a new standard of...

lung cancer
thyroid cancer

RET Inhibitor Selpercatinib Achieves Durable Responses in Majority of Patients With RET Gene Fusions

For patients with non–small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses in the majority of participants in the phase I/II LIBRETTO-001 trial, according to researchers from The University of...

lung cancer

Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients...

lung cancer

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Misako Nagasaka, MD, of the Barbara Ann Karmanos Cancer Institute, discusses results of the ORIENT-11 trial, which showed that, although sintilimab plus pemetrexed and platinum significantly improved progression-free survival, the combination only nominally improved overall survival in patients...

issues in oncology

Developing Policies to Address Patient Racial Bias and Race-Based Provider Requests

Public momentum for efforts to address structural and systemic racism has led many health-care institutions to consider how they can work to bring about positive change. In this column, drawing on important recent work by Kimani Paul-Emile, JD, PhD, Professor of Law at Fordham University School of ...

head and neck cancer

Transoral Robotic Surgery May Improve Outcomes in Early-Stage Oropharyngeal Cancer

Robotic surgery for patients with early-stage oropharyngeal squamous cell cancer may be associated with improved health outcomes, including better long-term survival, according to a study published by Nguyen et al in JAMA Oncology. Transoral robotic surgery is a minimally invasive procedure in...

pancreatic cancer

Sortilin May Be a Potential Therapeutic Target in Pancreatic Cancer

In a study published by Gao et al in The American Journal of Pathology, scientists reported the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells. The investigators speculated that this finding may lead to the development of more effective treatment for...

Roswell Park Care Network and Oneida Health Name New Radiation Oncology Medical Director

Roswell Park Comprehensive Cancer Center and Oneida Health announced the appointment of Maya Mathew, MD, as Medical Director of the Dorothy G. Griffin Radiation Oncology Center in Oneida, New York, part of the Roswell Park Care Network. In her new position, Dr. Mathew will lead a team that includes ...

lung cancer

Two Organizations Collaborate to Evaluate the Utility of Liquid Biopsy in Treating Lung Cancer

The Cancer Research Institute and The Mark Foundation for Cancer Research have launched an innovative clinical trial that aims to demonstrate the utility of liquid biopsy in assessing responses of patients with lung cancer to immunotherapy (ClinicalTrials.gov identifier NCT04093167). If the trial...

Sanjiv Sam Gambhir, MD, PhD, Pioneer in Molecular Imaging, Dies at 57

Sanjiv Sam Gambhir, MD, PhD, Professor and Chair of Radiology at the Stanford School of Medicine and an internationally recognized pioneer in molecular imaging, died on July 18, 2020, of cancer. He was 57. The Virginia and D.K. Ludwig Professor of Cancer Research, Dr. Gambhir dedicated his career...

Gynecologic Cancer Advocate, Wendy Noelle Ericsson, Dies at Age 60

The Society of Gynecologic Oncology announced with sadness the death of Wendy Noelle Ericsson, an advocate and champion of the Foundation for Women’s Cancer, an advocacy group supporting research, education, and public awareness of gynecologic cancers. Ms. Ericsson’s death was due to complications...

Cornelius O. ‘Skip’ Granai, MD, Champion of Cancer Care for Women, Dies at 71

Cornelius O. “Skip” Granai, MD, Founder of the Program in Women’s Oncology at Women & Infants Hospital of Rhode Island, died on June 28, 2020, after a long bout with cancer. Dr. Granai strongly believed that cancer care for women should encompass both breast and gynecologic cancers, according...

Anticipate Difficulties by Patients in Adhering to Tamoxifen Therapy

Patients prescribed tamoxifen may not report when they interrupt or discontinue therapy, according to the results of a study published in the Journal of Clinical Oncology.1 Using blood draws to determine serum levels of tamoxifen among 1,177 premenopausal women with invasive breast cancer, the...

breast cancer

One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy

Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...

solid tumors

Tumeur Fibro-Plastique

The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...

Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers

Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...

integrative oncology

Ashwagandha

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present updated information on ...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Cambodia

The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Cambodia. The aim of this special feature is to highlight the global cancer burden for various countries of the...

Penn Medicine Receives $4.9 Million Grant to Improve Uptake of Cancer Care Best Practices

Although extensive research has suggested ways to ensure that patients receive evidence-based cancer care, putting these solutions into widespread practice can be a complex, challenging, and inefficient process. Now, a new grant awarded to the Perelman School of Medicine at the University of...

covid-19

Managing Cancer in Older Adults During the COVID-19 Pandemic

The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...

GO2 Foundation for Lung Cancer to Honor Charles Swanton, MD, With the 2020 Bonnie J. Addario Lectureship Award

The GO2 Foundation for Lung Cancer presented Charles Swanton, MD, PhD, FRCP, FMedSci, FRS, Senior Group Leader at the Francis Crick Institute, with the 2020 Bonnie J. Addario Lectureship Award at the Physicians’ Education Resource 21st Annual International Lung Cancer Congress. GO2 is recognizing...

Mary-Claire King, PhD, Honored With 2020 William L. McGuire Memorial Lecture Award

Mary-Claire King, PhD, will receive the William L. McGuire Memorial Lecture Award at the 2020 San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8 to 12, 2020. The William L. McGuire Memorial Lectureship was established in 1992 to commemorate Dr. McGuire’s significant...

Association of Community Cancer Centers Announces 2020 Innovator Award Recipients

The Association of Community Cancer Centers (ACCC) announced the winning programs for its 10th annual ACCC Innovator Awards, highlighting the year’s leading-edge strategies to challenges faced by oncology programs and practices across the country. The eight ACCC Innovator Award winners feature...

David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline

For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the...

multiple myeloma

How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome

The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...

cost of care

How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs

Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD; Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...

ASCO Answers Guide to Cancer Survivorship

The ASCO Answers Guide to Survivorship has the tools and resources your patients need to prepare for their lives after treatment. This vital resource will inform your patients and their caregivers about topics like the importance of follow-up care, concerns about recurrence, and managing long-term...

Advertisement

Advertisement



Advertisement